Study Identifies 2 Novel Mutations Responsible for Lung Cancer Resistance and How to Overcome It;
Kaiser Permanente Implements Value-Based Care/Payment Model;
UK National Health Services Increases Funds for Cancer Drugs Research;
NIH Launches Second Personalized Medicine Clinical Trial in Lung Cancer
Chicago, IL—Involving patients in the search for value in cancer care requires a better understanding of value and the development of more effective communication and teaching aids, according to a presentation at the 2014 American Society of Clinical Oncology (ASCO) meeting about defining value from different stakeholder perspectives.
Chicago, IL—Comparative effectiveness research (CER) and cost-effectiveness analyses have helped to define value as it relates to gynecologic oncology, said speakers during an education session on maximizing value and quality in gynecologic cancer care, at the 2014 American Society of Clinical Oncology meeting.
Tampa, FL—Patients with HER2-positive metastatic breast cancer consume 2.5 times more financial resources in their last 6 months of life, according to study results presented at the 2014 Academy of Managed Care Pharmacy meeting.
The high cost of cancer care follows patients well into survivorship, as annual medical costs and losses in productivity exceed those of people without cancer by 50% to 100%, a study for the Centers for Disease Control and Prevention (CDC) showed
Enzalutamide Extends Survival in Men with Metastatic Prostate Cancer
Lenalidomide plus R-CHOP Improves Outcomes in Patients with Lymphoma
Medicaid Coverage for Hematopoietic Cell Transplantation Varies among States
Gemtuzumab Ozogamicin Improves Overall Survival in Patients with AML, Warrants New Considerations
Predictive multiplex genomic (or genetic) testing may revolutionize the treatment of cancer by identifying targetable mutations in cancer genes for their individual patients. Although genetic testing is commercially available, its use in clinical practice has not been fully investigated.
Los Angeles, CA—Predictive testing offers greater value over prognostic testing to most stakeholders in cancer care, because it has a direct impact on disease treatment rather than simply predicting the course of the disease (which is, ironically, the role of prognostic testing), said S. Macey Johnson III, MBA, Vice President, Managed Care and Reimbursement, bioTheranostics, San Diego, CA, at the Fourth Annual Conference of the Association for Value-Based Cancer Care.
Los Angeles, CA—Much remains to be done to usher in the era of personalized healthcare, including better methods of drug development, said presenters at the Fourth Annual Conference of the Association for Value-Based Cancer Care.
Los Angeles, CA—Payers are scrambling to devise effective strategies to cope with rapidly changing access to quality cancer care as a result of escalating costs. At the Fourth Annual Conference of the Association for Value-Based Cancer Care, John Fox, MD, MHA, Associate Vice President of Medical Affairs at Priority Health, Grand Rapids, MI, tackled changing access and payer challenges in oncology.
Page 1 of 3
Results 1 - 10 of 24
  • Rheumatology Practice Management
  • Lynx CME
  • American Health & Drug Benefits
  • Value-Based Cancer Care
  • Value-Based Care in Myeloma
  • Value-Based Care in Neurology